CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics. The Post-Transplant Diagnostics segment develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell free DNA test initially used for kidney transplant patients. The Pre-Transplant Diagnostics segment develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and organs. It sells Olerup SSP, which is used to type human leukocyte antigen (HAL) alleles based on sequence-specific primer technology; Olerup QTYPE, a test kit for sequence based HLA typing; Olerup SBT, a test kit for sequence based HLA typing; and XM-ONE, a test that identifies a patient's antigens against HLA Class I or Class II, as well as antibodies against a donor's endothelium. This segment offers its products directly to customers, as well as through third-party distributors. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDNA
CUSIPN/A
Phone415-287-2300
Debt
Debt-to-Equity Ratio0.46
Current Ratio2.16
Quick Ratio1.83
Price-To-Earnings
Trailing P/E Ratio-33.97
Forward P/E Ratio-27.67
P/E GrowthN/A
Sales & Book Value
Annual Sales$48.32 million
Price / Sales19.57
Cash FlowN/A
Price / CashN/A
Book Value($0.21) per share
Price / Book-123.86
Profitability
EPS (Most Recent Fiscal Year)($0.77)
Net Income$-55,460,000.00
Net Margins-121.92%
Return on Equity-108.99%
Return on Assets-19.30%
Miscellaneous
Employees179
Outstanding Shares36,350,000
Market Cap$986.43 million
CareDx (NASDAQ:CDNA) Frequently Asked Questions
What is CareDx's stock symbol?
CareDx trades on the NASDAQ under the ticker symbol "CDNA."
How were CareDx's earnings last quarter?
CareDx Inc (NASDAQ:CDNA) released its earnings results on Thursday, August, 9th. The company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.07) by $0.03. The company had revenue of $17.82 million for the quarter, compared to the consensus estimate of $15.30 million. CareDx had a negative return on equity of 108.99% and a negative net margin of 121.92%. View CareDx's Earnings History.
When is CareDx's next earnings date?
What price target have analysts set for CDNA?
4 Wall Street analysts have issued 1 year price objectives for CareDx's shares. Their predictions range from $6.50 to $42.00. On average, they expect CareDx's share price to reach $20.1250 in the next year. This suggests that the stock has a possible downside of 24.0%. View Analyst Price Targets for CareDx.
What is the consensus analysts' recommendation for CareDx?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CareDx.
What are Wall Street analysts saying about CareDx stock?
Here are some recent quotes from research analysts about CareDx stock:
- 1. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $790M, which includes a discounted cash flow analysis based asset value of $803M for pre- and post-transplant tests, using a 15% discount rate and 2% terminal growth rate, excluding $13M debt and assuming 36.5M shares outstanding at the end of 3Q19." (9/18/2018)
- 2. According to Zacks Investment Research, "CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California. " (9/10/2018)
Are investors shorting CareDx?
CareDx saw a decline in short interest in the month of August. As of August 31st, there was short interest totalling 1,489,426 shares, a decline of 40.0% from the August 15th total of 2,480,768 shares. Based on an average daily trading volume, of 659,111 shares, the short-interest ratio is currently 2.3 days. Currently, 5.2% of the company's stock are sold short. View CareDx's Current Options Chain.
Who are some of CareDx's key competitors?
Some companies that are related to CareDx include Genomic Health (GHDX), Natera (NTRA), InVitae (NVTA), RadNet (RDNT), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), PotNetwork (POTN), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), OpGen (OPGN) and CBA Florida (CBAI).
Who are CareDx's key executives?
CareDx's management team includes the folowing people:
- Dr. Peter Maag, Pres, CEO & Director (Age 51)
- Mr. Michael Bell, Chief Financial Officer (Age 49)
- Dr. James P. Yee, Chief Medical Officer (Age 69)
- Dr. Mitchell J. Nelles, Chief Operating Officer (Age 65)
- Dr. John J. Sninsky Ph.D., Chief Scientific Officer (Age 68)
Has CareDx been receiving favorable news coverage?
Headlines about CDNA stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. CareDx earned a news and rumor sentiment score of 0.18 on Accern's scale. They also gave news stories about the company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for CareDx.
Who are CareDx's major shareholders?
CareDx's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fred Alger Management Inc. (9.25%), BlackRock Inc. (6.41%), Gagnon Securities LLC (5.56%), Gagnon Advisors LLC (2.74%), Royce & Associates LP (2.46%) and RTW Investments LP (2.10%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Mitchell J Nelles, Neil Gagnon, Peter Maag and Sasha King. View Institutional Ownership Trends for CareDx.
Which major investors are selling CareDx stock?
CDNA stock was sold by a variety of institutional investors in the last quarter, including Private Wealth Partners LLC, Royce & Associates LP, EAM Investors LLC, Macquarie Group Ltd., Woodmont Investment Counsel LLC, EAM Global Investors LLC, California Public Employees Retirement System and Thompson Davis & CO. Inc.. Company insiders that have sold CareDx company stock in the last year include James P Yee, Michael Brian Bell, Mitchell J Nelles, Peter Maag and Sasha King. View Insider Buying and Selling for CareDx.
Which major investors are buying CareDx stock?
CDNA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Fred Alger Management Inc., Northern Trust Corp, RTW Investments LP, Casdin Capital LLC, Point72 Asset Management L.P., Gagnon Securities LLC and Russell Investments Group Ltd.. Company insiders that have bought CareDx stock in the last two years include Michael Brian Bell, Neil Gagnon and Peter Maag. View Insider Buying and Selling for CareDx.
How do I buy shares of CareDx?
Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CareDx's stock price today?
One share of CDNA stock can currently be purchased for approximately $26.48.
How big of a company is CareDx?
CareDx has a market capitalization of $986.43 million and generates $48.32 million in revenue each year. The company earns $-55,460,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. CareDx employs 179 workers across the globe.
How can I contact CareDx?
CareDx's mailing address is 3260 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The company can be reached via phone at 415-287-2300 or via email at [email protected]
MarketBeat Community Rating for CareDx (NASDAQ CDNA)
MarketBeat's community ratings are surveys of what our community members think about CareDx and other stocks. Vote "Outperform" if you believe CDNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
